Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Mol Genet Metab ; 143(1-2): 108563, 2024 Aug 10.
Article in English | MEDLINE | ID: mdl-39168057

ABSTRACT

Molybdenum cofactor deficiency type A has successfully been treated in a small number of children with daily intravenous administration of cyclic pyranopterin monophosphate. Pharmacodynamic data for this novel treatment have not been published and alternative dosing intervals have not been explored. We monitored pharmacodynamic biomarkers of sulfite oxidase and xanthine oxidoreductase activity in three patients with MoCD-A for a period of 2 to 9 months after discontinuation of cPMP substitution. We found that the clinical and metabolic effects were sustained for longer than expected, over 7 days at least. Our data implicate a biological half-life of the molybdenum cofactor dependent enzyme activities of approximately 3 days and suggest the possibility that less frequent than once daily dosing intervals could be a safe alternative to current practice.

2.
Mol Genet Metab ; 129(2): 98-105, 2020 02.
Article in English | MEDLINE | ID: mdl-31383595

ABSTRACT

The outcome of 110 patients with paediatric onset mucopolysaccharidosis II (MPS II) since the commercial introduction of enzyme replacement therapy (ERT) in England in 2007 is reported. Median length of follow up was 10 years 3 months (range = 1 y 2 m to 18 years 6 month). 78 patients were treated with ERT, 18 had no ERT or disease modifying treatment 7 had haematopoietic stem cell transplant, 4 experimental intrathecal therapy and 3 were lost to follow up. There is clear evidence of improved survival (median age of death of ERT treated (n = 16) = 15.13 years (range = 9.53 to 20.58 y), and untreated (n = 17) = 11.43 y (0.5 to 19.13 y) p = .0005). Early introduction of ERT improved respiratory outcome at 16 years, the median FVC (% predicted) of those in whom ERT initiated <8 years = 69% (range = 34-86%) and 48% (25-108) (p = .045) in those started >8 years. However, ERT appears to have minimal impact on hearing, carpal tunnel syndrome or progression of cardiac valvular disease. Cardiac valvular disease occurred in 18/46 (40%), with progression occurring most frequently in the aortic valve 13/46 (28%). The lack of requirement for neurosurgical intervention in the first 8 years of life suggests that targeted imaging based on clinical symptomology would be safe in this age group after baseline assessments. There is also emerging evidence that the neurological phenotype is more nuanced than the previously recognized dichotomy of severe and attenuated phenotypes in patients presenting in early childhood.


Subject(s)
Enzyme Replacement Therapy , Mucopolysaccharidosis II/drug therapy , Adolescent , Child , Child, Preschool , Data Collection , Disease Progression , England , Follow-Up Studies , Humans , Infant , Mucopolysaccharidosis II/mortality , Phenotype , Retrospective Studies , Time Factors , Treatment Outcome
3.
J Hum Nutr Diet ; 27(6): 533-41, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24387232

ABSTRACT

BACKGROUND: There is scarce evidence available with respect to an evaluation of the role of low protein staple foods (LPSF) in the management of phenylketonuria (PKU). The present study explored beliefs, acceptability and issues around the use of LPSF by people with PKU or their carers. METHODS: A semi-anonymous questionnaire was posted to 178 people with PKU in Scotland (104 children, aged 2-17 years, and 74 adults). Questions explored were: the type and amount of LPSF ordered; perceptions on use and usefulness of LPSF; acceptability of the LPSF sensory properties (i.e. taste, smell, texture, appearance); support for the supply and use of LPSF; and comments from primary healthcare professionals regarding dispensing and prescription. RESULTS: Eighty-two individuals responded (46% response rate): 97% perceived that LPSF were useful for PKU management; more than 85% reported that LPSF were important for phenylalanine control, satisfying appetite, and diet variety. The most common LPSF ordered were pasta/rice/cous cous, flour, biscuits and bread. Fifty percent of respondents ordered <51% of the recommended unit allowance of LPSF. The sensory properties of LPSF were well perceived. Forty-nine percent (n = 39) had received a comment from primary healthcare staff regarding the prescription or dispensing of LPSF; 59% (n = 23) received negative comments, the majority of which came within general practitioner surgeries. CONCLUSIONS: There is a positive attitude and perception on the use and usefulness of LPSF in the management of PKU. Issues with respect to the supply and provision of LPSF within primary health care may indicate poor communication between specialists and primary healthcare professionals or a lack of scientific evidence demonstrating their clinical effectiveness.


Subject(s)
Attitude to Health , Diet, Protein-Restricted , Phenylalanine/administration & dosage , Phenylketonurias/diet therapy , Adolescent , Adult , Child , Child, Preschool , Diet Surveys , Female , Humans , Male , Oryza , Scotland , Surveys and Questionnaires , Triticum
4.
J Inherit Metab Dis ; 32(5): 630, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19642010

ABSTRACT

Objectives Isolated methylmalonic acidurias (MMAurias) are caused by deficiency of methylmalonyl-CoA mutase or by defects in the synthesis of its cofactor 5'-deoxyadenosylcobalamin. The aim of this study was to evaluate which parameters best predicted the long-term outcome. Methods Standardized questionnaires were sent to 20 European metabolic centres asking for age at diagnosis, birth decade, diagnostic work-up, cobalamin responsiveness, enzymatic subgroup (mut(0), mut(-), cblA, cblB) and different aspects of long-term outcome. Results 273 patients were included. Neonatal onset of the disease was associated with increased mortality rate, high frequency of developmental delay, and severe handicap. Cobalamin non-responsive patients with neonatal onset born in the 1970s and 1980s had a particularly poor outcome. A more favourable outcome was found in patients with late onset of symptoms, especially when cobalamin responsive or classified as mut(-). Prevention of neonatal crises in pre-symptomatically diagnosed newborns was identified as a protective factor concerning handicap. Chronic renal failure manifested earlier in mut(0) patients than in other enzymatic subgroups. Conclusion Outcome in MMAurias is best predicted by the enzymatic subgroup, cobalamin responsiveness, age at onset and birth decade. The prognosis is still unfavourable in patients with neonatal metabolic crises and non-responsiveness to cobalamin, in particular mut(0) patients.


Subject(s)
Amino Acid Metabolism, Inborn Errors/diagnosis , Biomarkers/analysis , Methylmalonyl-CoA Mutase/deficiency , Adolescent , Adult , Age of Onset , Amino Acid Metabolism, Inborn Errors/epidemiology , Amino Acid Metabolism, Inborn Errors/genetics , Amino Acid Metabolism, Inborn Errors/mortality , Child , Child, Preschool , Cobamides/deficiency , Cohort Studies , Female , Humans , Infant , Infant, Newborn , Male , Methylmalonyl-CoA Mutase/genetics , Outcome Assessment, Health Care , Prognosis , Survival Analysis , Young Adult
5.
J Inherit Metab Dis ; 31(3): 361-7, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18563634

ABSTRACT

The long-term outcome of patients with methylmalonic aciduria (MMA) is still uncertain due to a high frequency of complications such as chronic renal failure and metabolic stroke. The understanding of this disease is hampered by a huge variation in the management of these patients. The major aim of this study was to evaluate the current practice in different European metabolic centres. A standardized questionnaire was sent to 20 metabolic centres asking for standard procedures for confirmation of diagnosis, testing cobalamin responsiveness, dietary treatment, pharmacotherapy, and biochemical and clinical monitoring. Sixteen of 20 metabolic centres (80%) returned questionnaires on 183 patients: 89 of the patients were classified as mut(0), 36 as mut(-), 13 as cblA, 7 as cblB, and 38 as cblA/B. (1) Confirmation of diagnosis: All centres investigate enzyme activity by propionate fixation in fibroblasts; six centres also perform mutation analysis. (2) Cobalamin response: Ten centres follow standardized protocols showing large variations. A reliable exclusion of nonspecific effects has not yet been achieved by these protocols. (3) Long-term treatment: In cobalamin-responsive patients, most centres use hydroxocobalamin (1-14 mg/week i.m. or 5-20 mg/week orally), while two centres use cyanocobalamin. All cobalamin-nonresponsive patients and most cobalamin-responsive patients are supplemented with L: -carnitine (50-100 mg/kg per day). Fourteen centres use intestinal decontamination by antibiotic therapy. Most centres follow D-A-CH (n = 6) or Dewey (n = 4) recommendations for protein requirements. Fourteen centres regularly use precursor-free amino acid supplements. Standardized monitoring protocols are available in seven centres, again showing high variability.


Subject(s)
Amino Acid Metabolism, Inborn Errors/diagnosis , Methylmalonic Acid/urine , Adolescent , Adult , Amino Acid Metabolism, Inborn Errors/drug therapy , Child , Child, Preschool , Humans , Hydroxocobalamin/therapeutic use , Infant , Infant, Newborn , Vitamin B 12/therapeutic use
6.
Genet Couns ; 18(1): 119-23, 2007.
Article in English | MEDLINE | ID: mdl-17515308

ABSTRACT

We report on a patient with congenital distal limb contractures, characteristic face, prominent metopic sutures, narrow forehead, severe psychomotor and growth retardation, white matter lesions and failure to thrive. The child has many overlapping features with those reported previously by Chitayat. We suggest that the central nervous anomalies are responsible for the congenital contractures in Chitayat syndrome.


Subject(s)
Abnormalities, Multiple , Developmental Disabilities , Intellectual Disability , Limb Deformities, Congenital , Central Nervous System/abnormalities , Contracture/congenital , Facies , Humans , Infant, Newborn , Male , Muscles/abnormalities , Syndrome
8.
J Histochem Cytochem ; 40(2): 283-91, 1992 Feb.
Article in English | MEDLINE | ID: mdl-1552170

ABSTRACT

We investigated the temporal and spatial distribution of osteonectin during human embryonic and fetal development, using in situ hybridization and immunohistochemistry. Osteonectin gene expression was generally found in cells exhibiting high rates of matrix production/proliferation. In mineralized tissue, a strong signal was obtained in osteoblasts, odontoblasts, and chondrocytes of the upper hypertrophic and proliferative zones. Chondrocytes of the mineralized zone showed no expression throughout the different stages of development. Strong osteonectin expression was found in odontoblasts of developing teeth. In addition, osteonectin mRNA and protein were detected in several non-mineralized tissues: steroid-producing cells of the adrenal gland and the gonads, kidney (glomeruli), lung (bronchi), skin, megacaryocytes, and large vessels. Histochemistry confirmed the results and detected extracellular osteonectin in bone and in the zone of mineralized cartilage only. The localization of osteonectin in bone, cartilage, and teeth is consistent with a role in the initiation of mineralization. However, the organ-specific distribution in non-mineralized tissues suggests an important multifunction role of this protein during human development.


Subject(s)
Embryo, Mammalian/physiology , Embryonic and Fetal Development , Fetus/physiology , Osteonectin/genetics , Osteonectin/metabolism , RNA, Messenger/metabolism , Abortion, Spontaneous , Embryo, Mammalian/cytology , Female , Fetus/cytology , Gene Expression , Humans , Immunohistochemistry , Organ Specificity , Osteogenesis , Osteonectin/analysis , Pregnancy , RNA, Messenger/analysis
9.
Am J Pharmacogenomics ; 1(3): 189-201, 2001.
Article in English | MEDLINE | ID: mdl-12083967

ABSTRACT

5,10-Methylenetetrahydrofolate reductase (MTHFR) plays a key role in folate metabolism by channeling one-carbon units between nucleotide synthesis and methylation reactions. Severe enzyme deficiency leads to hyperhomocysteinemia and homocystinuria, with altered folate distribution and a phenotype that is characterized by damage to the nervous and vascular systems. Two frequent polymorphisms in the human MTHFR gene confer moderate functional impairment of MTHFR activity for homozygous mutant individuals. The C to T change at nucleotide position 677, whose functional consequences are dependent on folate status, has been extensively studied for its clinical consequences. A second polymorphism, an A to C change at nucleotide position 1298, is not as well characterized. Still equivocal are associations between MTHFR polymorphisms and vascular arteriosclerotic or thrombotic disease. Neural tube defects and pregnancy complications appear to be linked to impaired MTHFR function. Colonic cancer and acute leukemia, however, appear to be less frequent in individuals homozygous for the 677T polymorphism.MTHFR polymorphisms influence the homocysteine-lowering effect of folates and could modify the pharmacodynamics of antifolates and many other drugs whose metabolism, biochemical effects, or target structures require methylation reactions. However, only preliminary evidence exists for gene-drug interactions. This review summarizes the biochemical basis and clinical evidence for interactions between MTHFR polymorphisms and several disease entities, as well as potential interactions with drug therapies. Future investigations of MTHFR in disease should consider the influence of other variants of functionally-related genes as well as the medication regimen of the patients. Animal models for genetic deficiencies in folate metabolism will likely play a greater role in our understanding of folate-dependent disorders.


Subject(s)
Mutation , Oxidoreductases Acting on CH-NH Group Donors/genetics , Polymorphism, Genetic , Female , Genetics, Medical , Humans , Methylenetetrahydrofolate Reductase (NADPH2) , Oxidoreductases Acting on CH-NH Group Donors/deficiency , Oxidoreductases Acting on CH-NH Group Donors/metabolism , Polymorphism, Single Nucleotide , Pregnancy , Pregnancy Complications
10.
Ann Anat ; 181(1): 51-3, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10081559

ABSTRACT

An essential problem in the diagnosis of craniomandibular disorders is still the evaluation of the type and severity of the TMJ diseases. For a differential classification of TMJ diseases, we developed an electronic axiography system which facilitates a recording of lower jaw movements. It works 3-dimensionally and relates to the joints. The measuring system, which was internationally patented, is based on a linear resistive foil for the sagittal plane and an inductive gauge for the horizontal plane. The aim of this pilot study was to evaluate the usefulness of our electronic axiography system in obtaining a differential diagnosis of craniomandibular disorders. We examined 30 patients (60 joints) with complaints in the TMJ area (pain and TMJ sounds). Clinical examinations yielded only uncertain indications of TMJ disease. With the help of electronic axiography we could differentiate the TMJ diseases into microtrauma and macrotrauma. Both forms may show a loss of function and an audible TMJ clicking. 23 joints had a macrotrauma (disk displacement with reduction, 20 times; disk displacement without reduction, 3 times). In 8 joints, a microtrauma was found. 3 joints showed a subluxation. In 4 uncertain cases, the diagnosis was confirmed with the help of magnetic resonance imaging (MRI). All patients with a diagnosed arthrogenic disorder received adequate treatment with reposition splints. Our initial results show that 3-dimensional electronic axiography can be a good aid in further characterization of craniomandibular disorders and permits an effective therapy.


Subject(s)
Temporomandibular Joint Disorders/diagnosis , Female , Humans , Jaw Relation Record , Magnetic Resonance Imaging , Male , Pain , Temporomandibular Joint Disorders/physiopathology
11.
Clin Pediatr (Phila) ; 43(9): 837-43, 2004.
Article in English | MEDLINE | ID: mdl-15583780

ABSTRACT

Propionic acidemia (PA) is one of the most frequent organic acidurias, but information on the outcome of individuals with PA is rather limited. We present data of 49 patients with PA, which were gathered from 18 metabolic centers throughout Central Europe on the occasion of an international workshop. All patients were identified by selective metabolic screening, and 86% of them were classified as having early-onset PA owing to their presentation with clinical symptoms within the first 90 days of life. Mortality rate was one third, and details of symptoms and treatment of the surviving patients are discussed. The great variation of phenotypic expression of the disease and different therapeutic strategies (especially in regard to the degree of protein restriction) used at the various institutions involved in this study imply the need for a registry of PA patients and for a multicenter prospective treatment study.


Subject(s)
Amino Acid Metabolism, Inborn Errors/diagnosis , Amino Acid Metabolism, Inborn Errors/therapy , Propionates/blood , Child , Child, Preschool , Eating , Humans , Infant , Time Factors
12.
Eur J Endocrinol ; 162(5): 987-92, 2010 May.
Article in English | MEDLINE | ID: mdl-20164212

ABSTRACT

OBJECTIVE: The phenotype associated with heterozygous HNF4A gene mutations has recently been extended to include diazoxide responsive neonatal hypoglycemia in addition to maturity-onset diabetes of the young (MODY). To date, mutation screening has been limited to patients with a family history consistent with MODY. In this study, we investigated the prevalence of HNF4A mutations in a large cohort of patients with diazoxide responsive hyperinsulinemic hypoglycemia (HH). SUBJECTS AND METHODS: We sequenced the ABCC8, KCNJ11, GCK, GLUD1, and/or HNF4A genes in 220 patients with HH responsive to diazoxide. The order of genetic testing was dependent upon the clinical phenotype. RESULTS: A genetic diagnosis was possible for 59/220 (27%) patients. K(ATP) channel mutations were most common (15%) followed by GLUD1 mutations causing hyperinsulinism with hyperammonemia (5.9%), and HNF4A mutations (5%). Seven of the 11 probands with a heterozygous HNF4A mutation did not have a parent affected with diabetes, and four de novo mutations were confirmed. These patients were diagnosed with HI within the first week of life (median age 1 day), and they had increased birth weight (median +2.4 SDS). The duration of diazoxide treatment ranged from 3 months to ongoing at 8 years. CONCLUSIONS: In this large series, HNF4A mutations are the third most common cause of diazoxide responsive HH. We recommend that HNF4A sequencing is considered in all patients with diazoxide responsive HH diagnosed in the first week of life irrespective of a family history of diabetes, once K(ATP) channel mutations have been excluded.


Subject(s)
Congenital Hyperinsulinism/genetics , Diazoxide/therapeutic use , Hepatocyte Nuclear Factor 4/genetics , Hyperinsulinism/genetics , Hypoglycemia/genetics , Adolescent , Child , Child, Preschool , Cohort Studies , Congenital Hyperinsulinism/drug therapy , Female , Humans , Hyperinsulinism/drug therapy , Hypoglycemia/drug therapy , Infant , Infant, Newborn , Male , Mutation , Pedigree
15.
Atherosclerosis ; 195(2): e100-7, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17689540

ABSTRACT

OBJECTIVE: To investigate the lipotropic action of betaine on plasma lipoproteins and tissue lipids. METHODS AND RESULTS: Adult mice, wild type (+/+) or heterozygous (+/-) for a disruption of the methylenetetrahydrofolate reductase (Mthfr) gene, were supplemented with betaine for 1 year and compared with mice on control diets. Outcome measures were plasma homocysteine and lipoprotein levels, aortic and liver morphology, and liver staining for 3-nitrotyrosine (oxidative stress marker) and Apolipoprotein A-I (ApoA-I). We also investigated short-term effects of supplemental betaine on plasma lipoproteins in Mthfr +/+ and +/- mice. Both genotypes showed significantly lower plasma homocysteine after long-term betaine supplementation, and lower plasma triglycerides and higher HDL-cholesterol after both short- and long-term betaine. Lipid accumulation in liver and aortic wall tended to be lower in Mthfr+/+ compared to Mthfr+/- mice and in betaine-supplemented compared to unsupplemented mice. Nitrotyrosine staining was higher and ApoA-I staining was lower in livers of Mthfr+/- compared to Mthfr+/+ mice. Betaine did not affect staining of nitrotyrosine but increased ApoA-I staining. A significant negative correlation was observed between plasma homocysteine and liver ApoA-I. CONCLUSIONS: Mild MTHFR deficiency in mice is associated with increased risk for atherosclerotic disease. Betaine has a lipotropic effect, which is associated with a reduction in homocysteine, an increase in ApoA-I and an amelioration of the atherogenic risk profile.


Subject(s)
Apolipoprotein A-I/drug effects , Betaine/pharmacology , Homocysteine/drug effects , Hyperhomocysteinemia/drug therapy , Lipotropic Agents/pharmacology , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Animals , Animals, Genetically Modified , Aorta/pathology , Cholesterol , Disease Models, Animal , Fatty Liver/pathology , Immunohistochemistry , Mice , Time , Triglycerides/blood , Tyrosine/analogs & derivatives , Tyrosine/analysis
16.
Neuropediatrics ; 37(3): 163-5, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16967369

ABSTRACT

Gaucher disease, a rare lysosomal storage disease caused by deficiency of glucocerebrosidase, may present with gastrointestinal bleeding. We report about an 11-month-old boy suffering from acute neuronopathic Gaucher disease who died after massive gastrointestinal bleeding. A gastric ulcer was found as the sole bleeding source. The gastric mucosa showed marked infiltration with Gaucher cells, in particular around the ulcer. Alterations of the gastrointestinal mucosa offer a new explanation for gastrointestinal bleedings in this disease.


Subject(s)
Gastrointestinal Diseases/complications , Gaucher Disease/etiology , Hemorrhage/complications , Fatal Outcome , Gastrointestinal Diseases/pathology , Humans , Infant , Male , Postmortem Changes
17.
J Inherit Metab Dis ; 28(1): 99-102, 2005.
Article in English | MEDLINE | ID: mdl-15702411

ABSTRACT

A hitherto healthy 7-year-old girl underwent antiproliferative and antibiotic treatment owing to the diagnosis of T-cell lymphoma and concomitant bacterial infection. She developed an encephalopathic crisis associated with metabolic acidosis, hyponatraemia and severe hyperhomocysteinaemia and 5-oxoprolinuria. Laboratory tests normalized completely after recovery. Primary defects in glutathione metabolism could be excluded.


Subject(s)
Anti-Infective Agents/adverse effects , Hyperhomocysteinemia/etiology , Lymphoma, T-Cell/drug therapy , Pyrrolidonecarboxylic Acid/urine , Acidosis , Anions , Antineoplastic Agents/adverse effects , Child , Female , Glutathione/metabolism , Homocysteine/chemistry , Humans , Phenytoin/chemistry , Polymorphism, Genetic , Time Factors
18.
Mol Genet Metab ; 84(4): 313-6, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15781191

ABSTRACT

Maple syrup urine disease (MSUD) is a genetic metabolic disorder resulting from the defective activity of branched-chain 2-ketoacid dehydrogenase complex. Due to the metabolic block, high concentrations of the branched-chain amino acids (BCAA) leucine, valine, isoleucine, and allo-isoleucine as well as their corresponding branched-chain 2-keto acids accumulate in patients on a BCAA-unrestricted diet or during episodes with increased protein catabolism. Early diagnosis and management are essential to prevent permanent brain damage. Newborn screening by tandem MS allows for detection of elevated BCAA concentrations in blood in patients with classical MSUD before they show severe encephalopathic symptoms. Here, we report that newborn screening by expanded tandem MS enables for reversing the intoxication in newborns with MSUD within 24-48 h without any need for extraneous detoxification and thus decreasing the risk of brain damage during a particularly vulnerable period.


Subject(s)
Maple Syrup Urine Disease/diagnosis , Neonatal Screening/methods , Amino Acids, Branched-Chain/blood , Diet, Fat-Restricted , Early Diagnosis , Female , Humans , Infant Nutritional Physiological Phenomena , Infant, Newborn , Male , Maple Syrup Urine Disease/blood , Maple Syrup Urine Disease/diet therapy , Mass Spectrometry/methods , Pregnancy
19.
J Hosp Mark ; 5(1): 85-101, 1990.
Article in English | MEDLINE | ID: mdl-10109363

ABSTRACT

Health administration faculty are interested in publishing activities in academic research journals. Perceived institutional quality and faculty professional advancement are strongly influenced by faculty's propensity to publish articles in scholarly journals. A five-year review of 10 of the health administration field's research-oriented journals showed that between 1983 and 1988 publication activity was heavily concentrated among four to seven institutions. These institutions also tended to publish in a greater breadth of journals selected by our criteria.


Subject(s)
Faculty/statistics & numerical data , Hospital Administration/education , Publishing/statistics & numerical data , Research , Universities/statistics & numerical data , Periodicals as Topic , United States
20.
Health Care Manage Rev ; 14(4): 29-40, 1989.
Article in English | MEDLINE | ID: mdl-2557302

ABSTRACT

This article reports on who is writing articles in the practice-oriented health care management journals and what topics are covered along with the contribution levels of the faculty from the U.S. Health Services Administration education programs.


Subject(s)
Delivery of Health Care/organization & administration , Periodicals as Topic , Comprehensive Health Care/organization & administration , Humans , Publishing , United States , United States Substance Abuse and Mental Health Services Administration , Writing
SELECTION OF CITATIONS
SEARCH DETAIL